Evolution

H7a

Bench to Bedside: Medical Devices

Prototype to Commercial Device

Overview

A working prototype is the beginning of the expensive part. Between it and a device a hospital can buy sits a sequence of gates, each of which converts capital into evidence: a controlled design, verification that it performs outside the hands that built it, a clinical study if the pathway demands one, and the transition to making it repeatedly to a standard at a cost that leaves room for a business. This evolution teaches that sequence as capital architecture, with attention to the three decisions that most often determine what a device company is worth: when to freeze the design, how the pivotal study and the design interact, and when to commit to tooling.

Format

Online

Recommended for

Device founders moving from prototype toward production
Teams approaching a design freeze decision
Innovators planning a pivotal study
Founders facing a GMP or manufacturing transition
Hardware spinouts estimating cost of goods
Advisors assessing device development risk

THE LEARNING FRAMEWORK

The learning framework

The study that locked the wrong device

A team reaches a pivotal study with a device that works and a design they know is not final. Two features are still awkward, the assembly is more expensive than it needs to be, and everyone assumes these will be cleaned up before launch. The study begins. From that point the device under test is the device, because changing it invalidates the data being generated to support the submission. The awkward features ship. The expensive assembly becomes the cost of goods, and the cost of goods becomes the gross margin an acquirer models when they decide what the company is worth. The design freeze was treated as an engineering milestone and scheduled around the study. It was in fact the moment the company's unit economics were fixed, and it was made by people optimizing for the study rather than for the business the device would eventually have to be.

Why device gates get read as engineering

Everything in this sequence looks like engineering, so founders delegate it to engineers, who execute it well against the goal they are given, which is usually a working, compliant device on a schedule. That goal is not the same as the company's goal. Verification and validation prove the device meets its specification, not that the specification produces a business. Design controls create traceability, not margin. A contract manufacturer who can build a hundred units is not necessarily a partner who can build ten thousand at a price that supports a sales organization. Three decisions in this sequence are commercial rather than technical and are routinely made as though they were technical. When to freeze the design, which fixes cost of goods. How the pivotal study constrains the design, which removes your ability to improve it. And when to commit to tooling, which converts flexible capital into a fixed bet on a specific configuration, frequently before the market has confirmed the configuration is right.

Development sequenced as a business decision

Healthcare innovators who complete this evolution treat design freeze, study design, and tooling commitment as decisions with commercial consequences, made with the cost of goods and the eventual acquirer in view. They can lay out the gates between where they are and a commercial device, cost each one, and identify which retire the risks an investor or an acquirer actually prices. They understand what a manufacturing transition costs and why it consumes capital while the product appears unchanged. And they can read a contract manufacturing relationship as a structural commitment rather than as a vendor selection.

WHAT YOU WILL LEARN

By the end of this evolution, you will be able to:

Map the device development sequence as capital

Lay out the gates from breadboard through alpha, beta, verification and validation, and pilot production. Understand what each demands in evidence, capital, and time, and which ones retire risk that changes what the company is worth.

Time the design freeze deliberately

Understand that freezing the design fixes your cost of goods, and therefore your gross margin, and therefore what an acquirer will pay. Learn what forces the freeze, what it forecloses, and why freezing to accommodate a study schedule is a commercial decision made on a clinical calendar.

Structure a pivotal study around the device you intend to sell

Recognize that once a pivotal begins, the device under test becomes the device you commercialize, because design changes invalidate the data supporting your submission. Understand how study design and design freeze constrain each other, what a device pivotal costs, and how enrollment delay converts into dilution.

Avoid the premature tooling trap

Understand that tooling converts flexible capital into a fixed commitment to a specific configuration. Learn what triggers the commitment, what it costs to reverse, and why teams make it before the market has confirmed the configuration.

Read the GMP transition as a capital event

Understand what changes when a device moves from being built to being manufactured under a quality system: what it costs, how long it takes, and why the product appears not to change while a great deal of money is spent.

Select and structure a contract manufacturer

Evaluate a manufacturing partner as a structural commitment rather than a vendor choice. Understand what tooling ownership, minimum volumes, capacity, and exclusivity do to your flexibility and to what an acquirer inherits.

Model cost of goods against the business you intend to build

Connect design and manufacturing decisions to unit economics, and unit economics to gross margin, and gross margin to what a strategic acquirer will pay. Understand why a device that works at any cost is not yet a company.

Build a device that is straightforward to acquire

Understand what an acquirer inherits: a design history file, a quality system, supplier relationships, tooling, and a manufacturing process that either transfers cleanly or does not. Learn which of these are built years before an approach.

WHY THIS MATTERS

Why this matters

The configuration you lock is the configuration you manufacture, and its cost is the cost an acquirer models. That decision is usually made on an engineering or clinical schedule by people who are not thinking about gross margin.

Once the study begins, the device is fixed by the evidence being generated. Anything unresolved at that point is unresolved permanently, or it costs a new study.

Before tooling you can change the product. After it, changing the product means writing off the investment. Committing early feels like progress and removes the flexibility you may still need.

Making something reliably to a standard is a different problem from making it work, and it produces no visible change in the product while it is happening. Teams who have solved the first routinely underestimate the second.

Cost of goods, supplier relationships, tooling ownership, and whether the process transfers cleanly are all priced into an offer. A device with excellent clinical data and an unmanufacturable design is a smaller transaction.

Recommended for

Healthcare innovators navigating:

The transition from prototype to controlled design

A design freeze decision

Pivotal study design and its interaction with the device

Verification and validation planning

The GMP and quality system transition

Contract manufacturer selection and negotiation

Tooling commitment and cost of goods modeling

Preparing a device company for acquisition

FOR INSTITUTIONS

Faculty who understand the process move through it faster.

Academic medical centers, research universities, and health systems sponsor cohorts so that inventors arrive at the office of technology transfer prepared: complete disclosures, clean assignment records, and realistic expectations about pathway and timeline. Cohort training is available for faculty, residents, and research staff, with CME.

Learn more about institutional cohorts →

HOW TO GET STARTED

How to get started

Your path to becoming a Certified Professional Entrepreneur

1st Step

Reserve your seat

Your deposit reserves a place in the cohort. Twenty seats. No application, no admissions committee, no waiting on a decision.

2nd Step

Begin the evolutions

Structured online learning you work through on your own schedule. Lectures run under fifteen minutes. Each evolution carries reading, supporting material, working tools, and case studies drawn from real transactions.

3rd Step

Join the live sessions

Live discussion sessions on Zoom, facilitated by Chris and Christos. Not recorded. This is where the material meets your actual situation, and where the cohort becomes a network.

EXPAND YOUR KNOWLEDGE